EyePoint Pharmaceuticals Doses First Patients in Phase 3 Global Trials of DURAVYU™ for Diabetic Macular Edema

EyePoint, Inc. (Nasdaq: EYPT) has announced a significant milestone in its clinical development pipeline, dosing the first patients in both the pivotal global Phase 3 COMO and CAPRI trials of DURAVYU™ (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME). This development marks a critical advancement as DURAVYU becomes the only tyrosine kinase inhibitor (TKI) currently in Phase 3 clinical trials for DME, positioning EyePoint at the forefront of sustained-release ocular drug delivery innovation.

Key Points for Investors

• Initiation of Phase 3 Trials in DME: Both COMO and CAPRI are randomized, double-masked, on-label aflibercept-controlled non-inferiority studies. Approximately 240 patients will be enrolled in each trial, comprising both treatment-naïve and previously treated DME patients. Randomization is between DURAVYU 2.7mg (delivered via a single intravitreal injection and re-dosed every six months) and aflibercept, the leading anti-VEGF therapy.
• Multi-Mechanism of Action: DURAVYU delivers vorolanib, a selective TKI, that inhibits VEGF-mediated vascular permeability, PDGF, and IL-6 mediated inflammation. This multi-modal approach addresses both vascular leakage and inflammatory drivers of DME, potentially overcoming limitations of current anti-VEGF-only therapies.
• Potential First-in-Class and Best-in-Class Status: The company aims for DURAVYU to be the first and best-in-class TKI for DME, filling a substantial unmet need as up to two-thirds of DME patients show persistent active disease after anti-VEGF loading.
• Regulatory Alignment: The trial design follows a well-established non-inferiority regulatory pathway, leveraging the infrastructure and relationships developed in EyePoint’s parallel pivotal wet AMD (age-related macular degeneration) program. Importantly, the DME pivotal program has alignment with both the FDA and EMA, following a positive End of Phase 2 meeting with the FDA.
• Anticipated Data Readouts: Topline data for DME are expected in the second half of 2027, while data from the Phase 3 wet AMD program are anticipated to begin reporting in mid-2026. Positive results could be transformative for EyePoint’s market position and valuation.

Potentially Price-Sensitive Information for Shareholders

• Strong Competitive Position: If DURAVYU demonstrates non-inferiority or superiority in vision outcomes and treatment burden compared to aflibercept, it could become a new standard of care for DME and wet AMD, two of the largest multi-billion-dollar retinal disease markets. This would be a significant value inflection point for EyePoint.
• Durability and Differentiation: DURAVYU’s design allows for dosing every six months, offering a potential reduction in treatment burden for patients and an attractive value proposition for payers, physicians, and patients.
• Favorable Safety Profile: Across over 190 patients in four completed clinical trials (including three Phase 2 trials), DURAVYU has demonstrated a strong safety and tolerability profile, with no significant safety signals observed to date.
• Robust Phase 2 Data: The VERONA Phase 2 trial in DME met its primary and secondary endpoints, showing rapid and sustained improvement in both vision and retinal anatomy, and outperformed standard aflibercept dosing intervals.
• Intellectual Property and Exclusivity: Vorolanib is licensed exclusively to EyePoint for all ophthalmic diseases outside of China, Macao, Hong Kong, and Taiwan, providing geographical exclusivity in major global markets.
• Regulatory and Legal Risks: Investors should note ongoing uncertainties regarding regulatory approvals, potential FDA communications, and a prior FDA warning letter related to EyePoint’s Watertown, MA facility, as well as an August 2022 subpoena from the U.S. Attorney’s Office for the District of Massachusetts. These could impact timelines or introduce additional risk.

About Diabetic Macular Edema and DURAVYU™

Diabetic macular edema is a leading cause of vision loss in people with diabetes, with approximately 28 million affected worldwide. Current treatments (anti-VEGF biologics, corticosteroids, laser photocoagulation) are burdensome and do not fully address the underlying disease mechanisms. DURAVYU, utilizing EyePoint’s proprietary Durasert E™ bioerodible technology, could offer a more durable and comprehensive approach by targeting both angiogenesis and inflammation.

DURAVYU is also being evaluated for wet AMD, with two fully enrolled Phase 3 trials (LUGANO and LUCIA) comprising over 900 patients. These studies will provide data on every six-month dosing, a potentially unique competitive advantage.

Financial and Strategic Outlook

• EyePoint is a clinical-stage biopharmaceutical company with a proven track record, including four approved drugs over three decades and extensive experience in ocular drug delivery.
• The company’s manufacturing facility in Massachusetts is operational, although it has been subject to regulatory review.
• EyePoint’s future plans, including the advancement of DURAVYU and other pipeline assets such as EYP-2301, are subject to available funding, regulatory developments, and clinical trial outcomes.

Forward-Looking Statements and Risks

EyePoint’s statements regarding DURAVYU’s potential, regulatory timelines, and commercial opportunity are forward-looking and subject to significant risks and uncertainties. These include clinical trial results, regulatory approvals, manufacturing risks, competitive dynamics, and financial requirements. Investors should review the “Risk Factors” in EyePoint’s SEC filings for a comprehensive risk assessment.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. The information is based on company press releases and public filings, which may contain forward-looking statements subject to risks and uncertainties. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions.

View EyePoint, Inc. Historical chart here